U.S. Markets open in 7 hrs 55 mins
  • S&P Futures

    3,672.75
    +8.25 (+0.23%)
     
  • Dow Futures

    29,992.00
    +60.00 (+0.20%)
     
  • Nasdaq Futures

    12,508.00
    +45.75 (+0.37%)
     
  • Russell 2000 Futures

    1,850.80
    +3.60 (+0.19%)
     
  • Crude Oil

    46.39
    +0.75 (+1.64%)
     
  • Gold

    1,838.90
    +2.10 (+0.11%)
     
  • Silver

    24.12
    +0.03 (+0.14%)
     
  • EUR/USD

    1.2161
    +0.0012 (+0.0973%)
     
  • 10-Yr Bond

    0.9200
    0.0000 (0.00%)
     
  • Vix

    21.28
    +0.11 (+0.52%)
     
  • GBP/USD

    1.3464
    +0.0011 (+0.0835%)
     
  • USD/JPY

    103.8740
    +0.0140 (+0.0135%)
     
  • BTC-USD

    19,356.42
    +98.84 (+0.51%)
     
  • CMC Crypto 200

    379.79
    +5.38 (+1.44%)
     
  • FTSE 100

    6,490.27
    +26.88 (+0.42%)
     
  • Nikkei 225

    26,751.24
    -58.13 (-0.22%)
     

Arcus Biosciences to Participate in the Evercore ISI 3rd Annual HealthCONx Virtual Conference

·2 min read

Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference on Wednesday, December 2, 2020 at 10:30 a.m. Eastern Time.

A live audio webcast of the presentation will be available by visiting the "Investors" section of the Arcus website at www.arcusbio.com. A replay of the webcast will be available for at least two weeks following the live event.

About Arcus Biosciences
Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to create highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. Arcus currently has four molecules in clinical development: Etrumadenant (AB928), the first and only dual A2a/A2b adenosine receptor antagonist in the clinic, is being evaluated in multiple Phase 1b/2 studies across different indications, including prostate, colorectal, non-small cell lung, pancreatic and triple-negative breast cancers. AB680, the first small-molecule CD73 inhibitor in the clinic, is in Phase 1 development for first-line treatment of metastatic pancreatic cancer in combination with zimberelimab and gemcitabine/nab-paclitaxel. Domvanalimab (AB154), an anti-TIGIT monoclonal antibody and new potential immuno-oncology backbone therapy, is in a three-arm randomized Phase 2 study for first-line treatment of PD-L1-high metastatic non-small cell lung cancer evaluating zimberelimab monotherapy, domvanalimab with zimberelimab and domvanalimab plus AB928 with zimberelimab. Zimberelimab (AB122), Arcus’s anti-PD-1 monoclonal antibody, is also being evaluated in a Phase 1b study as monotherapy for cancers with no approved anti-PD-1 treatment options, and in various combinations across the portfolio. For more information about Arcus Biosciences, please visit www.arcusbio.com.

Source: Arcus Biosciences

View source version on businesswire.com: https://www.businesswire.com/news/home/20201118006044/en/

Contacts

Katherine Bock
VP Investor Relations & Corporate Strategy
(510) 694-6231
kbock@arcusbio.com